SCHEDULE 13D/A: Viking Global Investors Files Administrative Amendment to BridgeBio Pharma Stake Disclosure
Beneficial Ownership Amendment
Viking Global Investors LP and its affiliates filed Amendment No. 6 to their Schedule 13D for BridgeBio Pharma, Inc., primarily to update the title of the authorized contact person, while maintaining a significant beneficial ownership of 11.7%.
Summary
- This document is Amendment No. 6 to the Schedule 13D filing by Viking Global Investors LP and its affiliated entities concerning their beneficial ownership in BridgeBio Pharma, Inc.
- The sole purpose of this specific amendment is to change the title of the person authorized to receive notices and communications on the first page of the Schedule 13D.
- Viking Global Investors LP, along with individuals Ole Andreas Halvorsen, David C. Ott, and Rose Sharon Shabet, collectively report beneficial ownership of 22,055,375 shares of BridgeBio Pharma's Common Stock.
- This collective ownership represents 11.7% of the 188,989,802 shares of Common Stock outstanding as of November 5, 2024, as reported by BridgeBio Pharma, Inc. in its quarterly report on Form 10-Q filed on November 12, 2024.
- Other affiliated entities include Viking Global Performance LLC and Viking Global Equities Master Ltd., each beneficially owning 487,901 shares (0.3%).
- Viking Long Fund GP LLC and Viking Long Fund Master Ltd. each beneficially own 194,184 shares (0.1%).
- Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, and Viking Global Opportunities Illiquid Investments Sub-Master LP each beneficially own 21,373,290 shares (11.3%).
Sentiment
Score: 5
Explanation: The document is an administrative amendment to a beneficial ownership filing, primarily updating contact information. It contains no new substantive financial or operational information that would impact sentiment.
Future Outlook
NA
Industry Context
This filing is an administrative update to a significant ownership disclosure by a major institutional investor in a biotechnology company. It reflects ongoing compliance with SEC regulations for large shareholders rather than a specific industry trend or competitive action.
Stakeholder Impact
- Shareholders: Provides updated beneficial ownership percentages, confirming the continued significant stake held by Viking Global Investors and its affiliates.
- Regulatory Authorities: Ensures compliance with SEC disclosure requirements for significant shareholders.
Key Dates
| Date | Description |
|---|---|
| 2019-07-08 | Original Schedule 13D filed with the SEC. |
| 2021-02-09 | Date of authorization and designation letter for Scott M. Hendler to sign on behalf of O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet. |
| 2021-02-12 | Date Form 13G filed by Mr. Halvorsen, Mr. Ott, and Ms. Shabet, which included the authorization letter as an exhibit. |
| 2023-07-19 | Amendment No. 1 to Schedule 13D filed. |
| 2023-11-22 | Amendment No. 2 to Schedule 13D filed. |
| 2024-08-20 | Amendment No. 3 to Schedule 13D filed. |
| 2024-11-05 | Date as of which 188,989,802 shares of Common Stock of BridgeBio Pharma, Inc. were outstanding, as reported in the Issuer's quarterly report on Form 10-Q. |
| 2024-11-06 | Amendment No. 4 to Schedule 13D filed. |
| 2024-11-12 | Date BridgeBio Pharma, Inc. filed its quarterly report on Form 10-Q with the SEC, reporting outstanding shares. |
| 2025-01-31 | Date of event which requires filing of this statement (Amendment No. 5 filed). |
| 2025-03-12 | Date Amendment No. 6 to Schedule 13D was signed and filed. |
Keywords
BridgeBio Pharma, Viking Global Investors, Schedule 13D, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Amendment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.